[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-001", "question": "A 58-year-old man with a history of hypertrophic cardiomyopathy presents with recurrent syncope. Genetic testing reveals a mutation in the MYH7 gene. Echocardiography shows asymmetric septal hypertrophy with a left ventricular outflow tract gradient of 80 mmHg at rest. Despite optimal medical therapy with beta-blockers, he continues to experience symptoms. What is the most appropriate next step in management?", "options": ["Alcohol septal ablation", "Surgical myectomy", "Implantation of a dual-chamber pacemaker", "Addition of disopyramide", "Cardiac resynchronization therapy"], "answer": "D", "answer_index": 3, "explanation": "Addition of disopyramide is the most appropriate next step as it is recommended for symptomatic hypertrophic cardiomyopathy with obstruction refractory to beta-blockers, acting as a negative inotrope to reduce the gradient. Alcohol septal ablation and surgical myectomy are invasive options considered only after failure of medical therapy including disopyramide. Pacemaker implantation and cardiac resynchronization therapy are not first-line for outflow tract obstruction in this context.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: K (Miskeyed). Verdict: Miskeyed. Key clues: 58-year-old, obstructive HCM with 80 mmHg gradient, recurrent syncope, refractory to beta-blockers. The 2020 AHA/ACC guidelines give Class I recommendation for septal reduction therapy (surgical myectomy preferred in suitable candidates) for patients with recurrent syncope due to LVOT obstruction and gradient ≥50 mmHg refractory to medical therapy. While disopyramide is a reasonable Class IIa add-on, it is NOT the 'most appropriate' next step in this severe scenario. Surgical myectomy (B) is the unique best answer as the gold standard for a 58-year-old patient without mentioned comorbidities. Alcohol ablation (A) is a reasonable alternative but less preferred for younger patients. The keyed answer D contradicts guideline-prioritized management for syncope with severe obstruction. Medical accuracy: 2—major error in management sequencing that could lead to inappropriate delay of definitive therapy. Minimal fix: Change key to B and revise rationale to emphasize Class I indication for septal reduction in syncope with severe gradient.\",\"medical_accuracy_score\":    \t\"2\",\"logical_validity\": false,\"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: K (Miskeyed). Verdict: Miskeyed. Key clues: 58-year-old, obstructive HCM with 80 mmHg gradient, recurrent syncope, refractory to beta-blockers. The 2020 AHA/ACC guidelines give Class I recommendation for septal reduction therapy (surgical myectomy preferred in suitable candidates) for patients with recurrent syncope due to LVOT obstruction and gradient ≥50 mmHg refractory to medical therapy. While disopyramide is a reasonable Class IIa add-on, it is NOT the 'most appropriate' next step in this severe scenario. Surgical myectomy (B) is the unique best answer as the gold standard for a 58-year-old patient without mentioned comorbidities. Alcohol ablation (A) is a reasonable alternative but less preferred for younger patients. The keyed answer D contradicts guideline-prioritized management for syncope with severe obstruction. Medical accuracy: 2—major error in management sequencing that could lead to inappropriate delay of definitive therapy. Minimal fix: Change key to B and revise rationale to emphasize Class I indication for septal reduction in syncope with severe gradient.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-002", "question": "A 4-year-old boy with a history of recurrent urinary tract infections is found to have vesicoureteral reflux on voiding cystourethrogram. Renal ultrasound shows mild hydronephrosis. Despite prophylactic antibiotics, he develops breakthrough infections. Genetic evaluation reveals a mutation in the PAX2 gene. What is the most likely associated syndrome?", "options": ["Denys-Drash syndrome", "Renal coloboma syndrome", "Branchio-oto-renal syndrome", "Alport syndrome", "Frasier syndrome"], "answer": "B", "answer_index": 1, "explanation": "Renal coloboma syndrome is associated with PAX2 mutations, characterized by renal hypoplasia, vesicoureteral reflux, and optic nerve colobomas. Denys-Drash and Frasier syndromes involve WT1 mutations, while Alport syndrome relates to collagen IV defects. Branchio-oto-renal syndrome is linked to EYA1 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V. Verdict: Correct best answer. The stem's PAX2 mutation is the sole discriminating clue; renal coloboma syndrome is the established PAX2-associated disorder. Key stem clues: 4-year-old with VUR, recurrent UTIs, hydronephrosis, and confirmed PAX2 mutation. The question asks for the most likely associated syndrome based on genotype. Renal coloboma syndrome (B) correctly maps to PAX2 mutations, while Denys-Drash/Frasier (WT1), Branchio-oto-renal (EYA1), and Alport (COL4A) have distinct genetic etiologies. No internal contradictions exist. The stem omits optic nerve colobomas—a cardinal feature—but this does not impair answer selection since the genetic result is provided. Alternative options are clearly inferior as they represent different gene defects. Medical accuracy is sound: PAX2 mutations cause renal coloboma syndrome, characterized by renal hypoplasia/dysplasia and VUR. The item tests recall of gene-syndrome pairings appropriate for board exams. Minimal fix: Add 'with optic nerve colobomas' to the stem to fully represent the syndrome phenotype, though not required for validity.\",\"medical_accuracy_score\":   \"4\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V. Verdict: Correct best answer. The stem's PAX2 mutation is the sole discriminating clue; renal coloboma syndrome is the established PAX2-associated disorder. Key stem clues: 4-year-old with VUR, recurrent UTIs, hydronephrosis, and confirmed PAX2 mutation. The question asks for the most likely associated syndrome based on genotype. Renal coloboma syndrome (B) correctly maps to PAX2 mutations, while Denys-Drash/Frasier (WT1), Branchio-oto-renal (EYA1), and Alport (COL4A) have distinct genetic etiologies. No internal contradictions exist. The stem omits optic nerve colobomas—a cardinal feature—but this does not impair answer selection since the genetic result is provided. Alternative options are clearly inferior as they represent different gene defects. Medical accuracy is sound: PAX2 mutations cause renal coloboma syndrome, characterized by renal hypoplasia/dysplasia and VUR. The item tests recall of gene-syndrome pairings appropriate for board exams. Minimal fix: Add 'with optic nerve colobomas' to the stem to fully represent the syndrome phenotype, though not required for validity.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-003", "question": "In the emergency department, a 32-year-old woman presents with acute chest pain and dyspnea following a long-haul flight. CT pulmonary angiography confirms a segmental pulmonary embolism. She has a history of oral contraceptive use and a positive family history for thrombophilia. Laboratory testing shows elevated factor VIII levels. What is the most appropriate initial anticoagulant therapy?", "options": ["Low-molecular-weight heparin followed by warfarin", "Direct oral anticoagulant such as rivaroxaban", "Unfractionated heparin with thrombolysis", "Fondaparinux monotherapy", "Aspirin and clopidogrel combination"], "answer": "B", "answer_index": 1, "explanation": "Direct oral anticoagulants like rivaroxaban are preferred for initial treatment of pulmonary embolism in non-pregnant patients without severe renal impairment or active cancer. Low-molecular-weight heparin followed by warfarin is an alternative but less convenient. Thrombolysis is reserved for hemodynamically unstable cases, and antiplatelet therapy is insufficient for venous thromboembolism.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: U (Underspecified) with secondary M (Multiple answers defensible). Verdict: The keyed answer B (rivaroxaban) would be correct if the patient is not pregnant and has no severe renal impairment, but these critical details are omitted. Key discriminating clues: acute segmental PE after long‑haul flight, oral contraceptive use, family history of thrombophilia, and elevated factor VIII. Current CHEST/ACCP and ESC guidelines endorse a DOAC as first‑line therapy for acute VTE in non‑pregnant, non‑cancer patients with normal renal function; LMWH/warfarin is an acceptable alternative. Because pregnancy status and renal function are not stated, both B and A are defensible depending on unstated assumptions, making the item underspecified and allowing multiple best answers. No medical inaccuracies are present, but the item requires the examinee to assume normal renal function and non‑pregnancy. Minimal fix: Add a sentence stating the patient is not pregnant and has normal renal function, ensuring no contraindications to a DOAC.\",\n\"medical_accuracy_score\":  \t \t \t \t\"5\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U (Underspecified) with secondary M (Multiple answers defensible). Verdict: The keyed answer B (rivaroxaban) would be correct if the patient is not pregnant and has no severe renal impairment, but these critical details are omitted. Key discriminating clues: acute segmental PE after long‑haul flight, oral contraceptive use, family history of thrombophilia, and elevated factor VIII. Current CHEST/ACCP and ESC guidelines endorse a DOAC as first‑line therapy for acute VTE in non‑pregnant, non‑cancer patients with normal renal function; LMWH/warfarin is an acceptable alternative. Because pregnancy status and renal function are not stated, both B and A are defensible depending on unstated assumptions, making the item underspecified and allowing multiple best answers. No medical inaccuracies are present, but the item requires the examinee to assume normal renal function and non‑pregnancy. Minimal fix: Add a sentence stating the patient is not pregnant and has normal renal function, ensuring no contraindications to a DOAC.", "medical_accuracy_score": 5, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-004", "question": "A 45-year-old woman presents with symmetric polyarthritis, morning stiffness, and a rash on her trunk. Laboratory tests show positive anti-citrullinated protein antibodies and elevated inflammatory markers. Despite methotrexate therapy, her disease progresses. Genetic testing reveals a mutation in the NLRP3 gene. What is the most likely diagnosis?", "options": ["Rheumatoid arthritis", "Cryopyrin-associated periodic syndrome", "Adult-onset Still's disease", "Behçet's disease", "Systemic lupus erythematosus"], "answer": "B", "answer_index": 1, "explanation": "Cryopyrin-associated periodic syndrome involves NLRP3 mutations, presenting with arthritis, rash, and autoinflammatory features that may mimic rheumatoid arthritis but respond poorly to standard DMARDs. Rheumatoid arthritis typically lacks this genetic mutation and responds to methotrexate. Adult-onset Still's disease and others do not feature NLRP3 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: M (Multiple answers defensible), secondary U (Underspecified). Verdict: Not uniquely determinable. The stem presents conflicting core data: classic rheumatoid arthritis features (symmetric polyarthritis, morning stiffness, strongly RA-specific ACPA positivity) directly oppose the genetic finding (NLRP3 mutation). While CAPS is correctly linked to NLRP3, ACPA positivity is not a CAPS feature and is >95% specific for RA, making option A defensible as the clinical diagnosis with an incidental genetic variant. Conversely, option B is defensible if one prioritizes the explicit genetic test result. The vague 'rash on trunk' fails to discriminate (urticaria in CAPS vs rheumatoid nodules/vasculitis). The question is underspecified regarding mutation pathogenicity and how to weigh serology versus genetics. Medical accuracy is compromised by conflating distinct entities: CAPS is a rare autoinflammatory disease with different pathophysiology and typically lacks ACPA. This creates a misleading teaching point that could encourage over-reliance on genetic testing in classic RA. Score: 2 (inaccurate). Minimal fix: Replace ACPA positivity with CAPS-consistent features such as urticarial rash, fever, and negative autoantibodies to eliminate diagnostic ambiguity.\",\"medical_accuracy_score\":   \"2\",\"logical_validity\":false,\"logical_false_reason\":\"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: M (Multiple answers defensible), secondary U (Underspecified). Verdict: Not uniquely determinable. The stem presents conflicting core data: classic rheumatoid arthritis features (symmetric polyarthritis, morning stiffness, strongly RA-specific ACPA positivity) directly oppose the genetic finding (NLRP3 mutation). While CAPS is correctly linked to NLRP3, ACPA positivity is not a CAPS feature and is >95% specific for RA, making option A defensible as the clinical diagnosis with an incidental genetic variant. Conversely, option B is defensible if one prioritizes the explicit genetic test result. The vague 'rash on trunk' fails to discriminate (urticaria in CAPS vs rheumatoid nodules/vasculitis). The question is underspecified regarding mutation pathogenicity and how to weigh serology versus genetics. Medical accuracy is compromised by conflating distinct entities: CAPS is a rare autoinflammatory disease with different pathophysiology and typically lacks ACPA. This creates a misleading teaching point that could encourage over-reliance on genetic testing in classic RA. Score: 2 (inaccurate). Minimal fix: Replace ACPA positivity with CAPS-consistent features such as urticarial rash, fever, and negative autoantibodies to eliminate diagnostic ambiguity.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-005", "question": "A 28-year-old man with type 1 diabetes mellitus presents with recurrent hypoglycemia despite insulin dose adjustments. Continuous glucose monitoring shows nocturnal hypoglycemia. Laboratory evaluation reveals elevated proinsulin levels and a low C-peptide. What is the most likely underlying mechanism?", "options": ["Insulinoma", "Factitious hypoglycemia from exogenous insulin", "Adrenal insufficiency", "Autoimmune hypoglycemia", "Nesidioblastosis"], "answer": "B", "answer_index": 1, "explanation": "Factitious hypoglycemia from exogenous insulin is indicated by low C-peptide and elevated proinsulin due to suppressed endogenous insulin production. Insulinoma would show high C-peptide and proinsulin. Adrenal insufficiency typically causes hyperglycemia, and autoimmune hypoglycemia involves insulin antibodies with variable C-peptide.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity label: C (Contradiction) – the stem presents an internally inconsistent lab pattern (elevated proinsulin with low C‑peptide) that does not occur in any listed condition, making the item unsolvable. Verdict on keyed answer: No defensible answer. Key stem clues: type 1 diabetes, recurrent nocturnal hypoglycemia, low C‑peptide, elevated proinsulin. These findings cannot be reconciled: exogenous insulin (choice B) suppresses endogenous proinsulin production, so proinsulin should be low; insulinoma (A) and nesidioblastosis (E) raise C‑peptide; adrenal insufficiency (C) does not cause hyper‑insulinemic hypoglycemia; autoimmune hypoglycemia (D) requires insulin antibodies, which are absent. Main logical issue: internal inconsistency (C) – the lab values contradict known physiology, preventing a single best answer. Main medical accuracy issue: the rationale incorrectly claims exogenous insulin raises proinsulin, misrepresenting the C‑peptide/proinsulin relationship. Minimal fix: replace \\\"elevated proinsulin\\\" with \\\"low proinsulin\\\" to match exogenous insulin factitious hypoglycemia, or change the key to autoimmune hypoglycemia and add \\\"insulin antibodies present\\\" to the stem.\",\n\"medical_accuracy_score\":   \t\"2\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (Contradiction) – the stem presents an internally inconsistent lab pattern (elevated proinsulin with low C‑peptide) that does not occur in any listed condition, making the item unsolvable. Verdict on keyed answer: No defensible answer. Key stem clues: type 1 diabetes, recurrent nocturnal hypoglycemia, low C‑peptide, elevated proinsulin. These findings cannot be reconciled: exogenous insulin (choice B) suppresses endogenous proinsulin production, so proinsulin should be low; insulinoma (A) and nesidioblastosis (E) raise C‑peptide; adrenal insufficiency (C) does not cause hyper‑insulinemic hypoglycemia; autoimmune hypoglycemia (D) requires insulin antibodies, which are absent. Main logical issue: internal inconsistency (C) – the lab values contradict known physiology, preventing a single best answer. Main medical accuracy issue: the rationale incorrectly claims exogenous insulin raises proinsulin, misrepresenting the C‑peptide/proinsulin relationship. Minimal fix: replace \"elevated proinsulin\" with \"low proinsulin\" to match exogenous insulin factitious hypoglycemia, or change the key to autoimmune hypoglycemia and add \"insulin antibodies present\" to the stem.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-006", "question": "A 65-year-old man with ischemic cardiomyopathy and an ejection fraction of 25% develops sustained ventricular tachycardia. He is hemodynamically stable. Electrophysiology study identifies a reentrant circuit in the infarct border zone. Despite amiodarone therapy, episodes recur. What is the most appropriate next intervention?", "options": ["Catheter ablation", "Implantable cardioverter-defibrillator upgrade to biventricular", "Addition of mexiletine", "Stellate ganglionectomy", "Cardiac sympathetic denervation"], "answer": "A", "answer_index": 0, "explanation": "Catheter ablation is the most appropriate for recurrent ventricular tachycardia in ischemic cardiomyopathy refractory to antiarrhythmic drugs, targeting the reentrant circuit. ICD upgrade addresses heart failure but not arrhythmia substrate directly. Mexiletine addition is less effective for scar-related VT, and surgical options like ganglionectomy are reserved for refractory cases.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: V (Valid). Verdict: Correct best answer. The stem provides high-yield discriminators: ischemic cardiomyopathy (EF 25%), recurrent sustained VT despite amiodarone, electrophysiology-confirmed reentrant circuit in infarct border zone, and hemodynamic stability. These point unequivocally to catheter ablation (A) as the next intervention per AHA/ACC/HRS guidelines for drug-refractory scar-related VT. No logical flaws: a single best answer is defensible without unstated assumptions. Alternative options are correctly positioned as inferior: ICD upgrade to biventricular (B) treats dyssynchrony, not VT substrate; mexiletine (C) offers modest adjunctive benefit but is not preferred over ablation; stellate ganglionectomy (D) and cardiac sympathetic denervation (E) are invasive, non-first-line options reserved for truly refractory cases after ablation failure. Medical accuracy is gold-standard: aligns with contemporary evidence (SMASH-VT, VANISH, BERLIN VT) and standard-of-care algorithms. The explanation accurately reflects guideline hierarchy. No contradictions or underspecification. Minimal fix: none required; item is examination-ready as written.\",\n\"medical_accuracy_score\":   \t\"5\",\n\"logical_validity\": true,\n\"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. The stem provides high-yield discriminators: ischemic cardiomyopathy (EF 25%), recurrent sustained VT despite amiodarone, electrophysiology-confirmed reentrant circuit in infarct border zone, and hemodynamic stability. These point unequivocally to catheter ablation (A) as the next intervention per AHA/ACC/HRS guidelines for drug-refractory scar-related VT. No logical flaws: a single best answer is defensible without unstated assumptions. Alternative options are correctly positioned as inferior: ICD upgrade to biventricular (B) treats dyssynchrony, not VT substrate; mexiletine (C) offers modest adjunctive benefit but is not preferred over ablation; stellate ganglionectomy (D) and cardiac sympathetic denervation (E) are invasive, non-first-line options reserved for truly refractory cases after ablation failure. Medical accuracy is gold-standard: aligns with contemporary evidence (SMASH-VT, VANISH, BERLIN VT) and standard-of-care algorithms. The explanation accurately reflects guideline hierarchy. No contradictions or underspecification. Minimal fix: none required; item is examination-ready as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-007", "question": "An 8-year-old girl with short stature and failure to thrive undergoes evaluation. Bone age is delayed, and laboratory tests show low IGF-1 with normal growth hormone stimulation. Genetic testing reveals a mutation in the IGF1R gene. What is the most appropriate management strategy?", "options": ["Recombinant growth hormone therapy", "IGF-1 replacement therapy", "Nutritional supplementation", "Thyroid hormone replacement", "Corticosteroid therapy"], "answer": "B", "answer_index": 1, "explanation": "IGF-1 replacement therapy is indicated for IGF1R mutations causing primary IGF-1 deficiency resistant to growth hormone. Recombinant growth hormone would be ineffective due to receptor defect. Nutritional or hormonal supplements like thyroid or corticosteroids do not address the underlying IGF-1 resistance.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Keyed answer is correct and uniquely best. The stem establishes primary IGF-1 resistance: childhood short stature with delayed bone age, low IGF-1 despite normal GH stimulation, and pathognomonic IGF1R mutation. These findings specifically indicate IGF-1 receptor dysfunction where GH therapy would be ineffective. Option B (IGF-1 replacement) directly bypasses the receptor defect and is the standard treatment for severe primary IGF-1 deficiency/resistance. Option A fails because intact GH stimulation demonstrates adequate GH production, making exogenous GH futile. Option C is supportive but not disease-specific. Option D is irrelevant without thyroid dysfunction. Option E is contraindicated as steroids impair growth. No internal contradictions exist, and each distractor has a clear, stem-based rationale for exclusion. The item accurately reflects current endocrine practice: mecasermin (recombinant IGF-1) is indicated for IGF-1 deficiency unresponsive to GH, including IGF1R mutations. Minor limitation: rare condition may lack large trial data, but pathophysiologic reasoning is sound and board-appropriate. Minimal fix: None required; item is exam-ready.\",\"medical_accuracy_score\":  \t\"4\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Keyed answer is correct and uniquely best. The stem establishes primary IGF-1 resistance: childhood short stature with delayed bone age, low IGF-1 despite normal GH stimulation, and pathognomonic IGF1R mutation. These findings specifically indicate IGF-1 receptor dysfunction where GH therapy would be ineffective. Option B (IGF-1 replacement) directly bypasses the receptor defect and is the standard treatment for severe primary IGF-1 deficiency/resistance. Option A fails because intact GH stimulation demonstrates adequate GH production, making exogenous GH futile. Option C is supportive but not disease-specific. Option D is irrelevant without thyroid dysfunction. Option E is contraindicated as steroids impair growth. No internal contradictions exist, and each distractor has a clear, stem-based rationale for exclusion. The item accurately reflects current endocrine practice: mecasermin (recombinant IGF-1) is indicated for IGF-1 deficiency unresponsive to GH, including IGF1R mutations. Minor limitation: rare condition may lack large trial data, but pathophysiologic reasoning is sound and board-appropriate. Minimal fix: None required; item is exam-ready.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-008", "question": "In the emergency department, a 50-year-old man presents with severe abdominal pain and vomiting. CT scan shows acute pancreatitis with necrosis. He develops hypotension and acute kidney injury. Serum triglycerides are 1200 mg/dL. What is the most appropriate initial management for the hypertriglyceridemia?", "options": ["Plasmapheresis", "Insulin infusion", "Fibrates", "Niacin", "Statins"], "answer": "B", "answer_index": 1, "explanation": "Insulin infusion effectively lowers triglycerides in hypertriglyceridemic pancreatitis by enhancing lipoprotein lipase activity. Plasmapheresis is reserved for severe cases not responding to insulin. Fibrates, niacin, and statins are long-term therapies not suitable for acute management.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity: V (Valid). Verdict: Correct best answer. Key stem clues: severe hypertriglyceridemia (1200 mg/dL) causing acute necrotizing pancreatitis with organ failure (hypotension, AKI); question asks for *initial* management. Insulin infusion is the established first-line therapy for hypertriglyceridemic pancreatitis, activating lipoprotein lipase to rapidly lower TG levels. Plasmapheresis is reserved for refractory cases or extreme TG (>2000 mg/dL) with ongoing organ failure, not initial therapy. Fibrates, niacin, and statins are chronic therapies inappropriate for acute stabilization. The keyed answer B is well-supported by AACE/ACG guidelines and standard board expectations. No internal contradictions exist; options are mutually exclusive and permit clear discrimination. Medical accuracy is high: the mechanism and hierarchy of therapies are correctly represented. Minor nuance: optimal insulin administration requires concurrent dextrose to prevent hypoglycemia, an implementation detail not required for answer selection. No fix is strictly necessary; for enhanced precision, the stem could specify 'insulin infusion with dextrose' or option B could read 'Insulin infusion (with dextrose),' but this does not affect the item's validity.\",\"medical_accuracy_score\":   \"4\",\"logical_validity\": true,\"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: V (Valid). Verdict: Correct best answer. Key stem clues: severe hypertriglyceridemia (1200 mg/dL) causing acute necrotizing pancreatitis with organ failure (hypotension, AKI); question asks for *initial* management. Insulin infusion is the established first-line therapy for hypertriglyceridemic pancreatitis, activating lipoprotein lipase to rapidly lower TG levels. Plasmapheresis is reserved for refractory cases or extreme TG (>2000 mg/dL) with ongoing organ failure, not initial therapy. Fibrates, niacin, and statins are chronic therapies inappropriate for acute stabilization. The keyed answer B is well-supported by AACE/ACG guidelines and standard board expectations. No internal contradictions exist; options are mutually exclusive and permit clear discrimination. Medical accuracy is high: the mechanism and hierarchy of therapies are correctly represented. Minor nuance: optimal insulin administration requires concurrent dextrose to prevent hypoglycemia, an implementation detail not required for answer selection. No fix is strictly necessary; for enhanced precision, the stem could specify 'insulin infusion with dextrose' or option B could read 'Insulin infusion (with dextrose),' but this does not affect the item's validity.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-009", "question": "A 35-year-old woman with seropositive rheumatoid arthritis on infliximab develops fever, weight loss, and lymphadenopathy. Biopsy shows non-caseating granulomas. Serum angiotensin-converting enzyme is elevated. What is the most likely diagnosis?", "options": ["Tuberculosis reactivation", "Infliximab-induced sarcoidosis", "Lymphoma", "Fungal infection", "Amyloidosis"], "answer": "B", "answer_index": 1, "explanation": "Infliximab-induced sarcoidosis is a rare complication of TNF inhibitors, presenting with granulomatous inflammation mimicking sarcoidosis. Tuberculosis would show caseating granulomas and positive cultures. Lymphoma or infections are differentials but less likely without specific evidence.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V. Verdict: Correct best answer. Key stem clues: 35-year-old woman with seropositive RA on infliximab (TNF-α inhibitor) develops systemic symptoms (fever, weight loss, lymphadenopathy) plus non-caseating granulomas on biopsy and elevated serum ACE. This triad specifically indicates a TNF inhibitor-induced sarcoid-like reaction. Main logical issue: None; the item is well-constructed. The non-caseating granuloma finding is the critical discriminator that eliminates TB reactivation (which would be caseating) and lymphoma (which would show malignant cells). Alternative options are appropriately inferior: fungal infection would require specific exposure or organism identification, and amyloidosis produces Congo-red positive deposits rather than granulomas. Medical accuracy: Fully consistent with current literature recognizing TNF inhibitor-associated sarcoidosis as a paradoxical reaction; elevated ACE is a valid supportive biomarker. The rationale correctly distinguishes entities. No medical inaccuracies or outdated concepts. Minimal fix: None required; the item is unambiguous and board-examination ready as written.\",\"medical_accuracy_score\":   \t\"4\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. Key stem clues: 35-year-old woman with seropositive RA on infliximab (TNF-α inhibitor) develops systemic symptoms (fever, weight loss, lymphadenopathy) plus non-caseating granulomas on biopsy and elevated serum ACE. This triad specifically indicates a TNF inhibitor-induced sarcoid-like reaction. Main logical issue: None; the item is well-constructed. The non-caseating granuloma finding is the critical discriminator that eliminates TB reactivation (which would be caseating) and lymphoma (which would show malignant cells). Alternative options are appropriately inferior: fungal infection would require specific exposure or organism identification, and amyloidosis produces Congo-red positive deposits rather than granulomas. Medical accuracy: Fully consistent with current literature recognizing TNF inhibitor-associated sarcoidosis as a paradoxical reaction; elevated ACE is a valid supportive biomarker. The rationale correctly distinguishes entities. No medical inaccuracies or outdated concepts. Minimal fix: None required; the item is unambiguous and board-examination ready as written.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-010", "question": "A 42-year-old woman with acromegaly undergoes transsphenoidal surgery, but IGF-1 levels remain elevated postoperatively. She declines further surgery. What is the most appropriate pharmacologic therapy?", "options": ["Cabergoline", "Pegvisomant", "Octreotide", "Pasireotide", "Bromocriptine"], "answer": "B", "answer_index": 1, "explanation": "Pegvisomant, a growth hormone receptor antagonist, is the most effective for normalizing IGF-1 in acromegaly resistant to surgery and somatostatin analogs. Octreotide and pasireotide are somatostatin analogs that may not suffice post-surgery. Dopamine agonists like cabergoline or bromocriptine are less potent for pure GH-secreting adenomas.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "kimi-k2-thinking", "judge_model_outputs_raw": "{\n\"analysis\": \"Validity: M (multiple answers defensible). The vignette describes persistent IGF-1 elevation after transsphenoidal surgery for acromegaly with refusal of further surgery, but omits any prior medical therapy. Current Endocrine Society guidelines advise initiating a somatostatin receptor ligand (octreotide or pasireotide) as first-line medical treatment after surgical failure; pegvisomant is indicated only after somatostatin analog intolerance or inadequate response. Consequently, both octreotide and pasireotide are equally defensible best choices, while pegvisomant (keyed answer) is not the preferred initial therapy. The explanation incorrectly assumes resistance to somatostatin analogs, which is not stated. Medical accuracy: The key contradicts guideline-based stepwise management, a moderate error that could mislead learners about first-line pharmacotherapy. The item also fails to differentiate between octreotide and pasireotide, which are both appropriate, adding to option overlap. Logical issue: Underspecified treatment history creates multiple plausible answers. Minimal fix: Add a sentence stating ‘She has already completed a 6‑month trial of octreotide LAR without adequate IGF‑1 normalization.’ This would make pegvisomant the clear next step and align the key with guidelines.\",\n\"medical_accuracy_score\":  \t \t \t\"3\",\n\"logical_validity\": false,\n\"logical_false_reason\": \"M\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity: M (multiple answers defensible). The vignette describes persistent IGF-1 elevation after transsphenoidal surgery for acromegaly with refusal of further surgery, but omits any prior medical therapy. Current Endocrine Society guidelines advise initiating a somatostatin receptor ligand (octreotide or pasireotide) as first-line medical treatment after surgical failure; pegvisomant is indicated only after somatostatin analog intolerance or inadequate response. Consequently, both octreotide and pasireotide are equally defensible best choices, while pegvisomant (keyed answer) is not the preferred initial therapy. The explanation incorrectly assumes resistance to somatostatin analogs, which is not stated. Medical accuracy: The key contradicts guideline-based stepwise management, a moderate error that could mislead learners about first-line pharmacotherapy. The item also fails to differentiate between octreotide and pasireotide, which are both appropriate, adding to option overlap. Logical issue: Underspecified treatment history creates multiple plausible answers. Minimal fix: Add a sentence stating ‘She has already completed a 6‑month trial of octreotide LAR without adequate IGF‑1 normalization.’ This would make pegvisomant the clear next step and align the key with guidelines.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}]